# 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is supplied in accordance with the requirements of the SMDA of 1990 and 21 CFR 807.92

The assigned 510(k) number is K093916

Date: August 18, 2010

# Submitted by:

Wallac Oy   
a subsidiary of PerkinElmer   
Mustionkatu 6   
20750 Turku, Finland

Contact person: Primary:

Kay A. Taylor Tele: 317-418-1735 Fax: 317-536-3064

# Secondary:

Susan HamannTele: 781-633-5872Fax: 781-633-5983

# Trade Name:

NeoBase Non-derivatized MSMS Kit

# Common Name:

NeoBase kit or Non-derivatized kit

# Classification Name:

Newborn screening test system for amino acids, free carnitine, and acylcarnitines using tandem mass spectrometry (21 CFR § 862.1055 /Product code NQL)

# Predicate device(s):

NeoBase Non-derivatized MSMS Kit, K083130

# Device description:

The measurement of amino acids, succinylacetone, free carnitine, and acylcarnitines with the NeoBase assay involves extraction of dried blood spots from newborns with a solution containing stable-isotope labeled internal standards and analysis using a tandem mass spectrometry (MSMS) system. The response of each analyte relative to their corresponding stable-isotope labeled internal standard is proportional to analyte concentration

# Intended Use: Indications for Use

The Neobase Non-derivatized MSMS reagent kit (for use on the PerkinElmer TQD MSMS Screening System) is intended for the measurement and evaluation of amino acids, succinylacetone, free carnitine, and acylcarnitine concentrations from newborn heel prick blood samples dried on filter paper.

Quantitative analysis of these analytes (Table 1) and their relationship with each other is intended to provide analyte concentration profiles that may aid in screening newborns for metabolic disorders.

Instruments: - PerkinElmer MS2 Tandem Mass Spectrometer System (MS2) - PerkinElmer MSMS Quattro Micro (Qmicro) Newborn Screening System - PerkinElmer MSMS TQD Newborn Screening System

Table 1. Analytes measured by the NeoBase Non-derivatized MSMS Kit.   

<table><tr><td colspan="1" rowspan="1">ANALYTE NAME</td><td colspan="1" rowspan="1">ABBREVIATION</td></tr><tr><td colspan="2" rowspan="1">Amino acids</td></tr><tr><td colspan="1" rowspan="1">Alanine</td><td colspan="1" rowspan="1">Ala</td></tr><tr><td colspan="1" rowspan="1">Arginine</td><td colspan="1" rowspan="1">Arg</td></tr><tr><td colspan="1" rowspan="1">Citrulline</td><td colspan="1" rowspan="1">Cit</td></tr><tr><td colspan="1" rowspan="1">Glycine</td><td colspan="1" rowspan="1">Gly</td></tr><tr><td colspan="1" rowspan="1">Leucine/lsoleucine/Hydroxyproline*</td><td colspan="1" rowspan="1">Leu/lle/Pro-OH</td></tr><tr><td colspan="1" rowspan="1">Methionine</td><td colspan="1" rowspan="1">Met</td></tr><tr><td colspan="1" rowspan="1">Ornithine</td><td colspan="1" rowspan="1">Orn</td></tr><tr><td colspan="1" rowspan="1">Phenylalanine</td><td colspan="1" rowspan="1">Phe</td></tr><tr><td colspan="1" rowspan="1">Proline</td><td colspan="1" rowspan="1">Pro</td></tr><tr><td colspan="1" rowspan="1">Tyrosine</td><td colspan="1" rowspan="1">Tyr</td></tr><tr><td colspan="1" rowspan="1">Valine</td><td colspan="1" rowspan="1">Val</td></tr><tr><td colspan="2" rowspan="1">Carnitines</td></tr><tr><td colspan="1" rowspan="1">Free carnitine</td><td colspan="1" rowspan="1">CO</td></tr><tr><td colspan="1" rowspan="1">Acetylcarnitine</td><td colspan="1" rowspan="1">C2</td></tr><tr><td colspan="1" rowspan="1">Propionylcarnitine</td><td colspan="1" rowspan="1">C3</td></tr><tr><td colspan="1" rowspan="1">Malonylcarnitine / 3-Hydroxy-butyrylcarnitine*</td><td colspan="1" rowspan="1">C3DC/C4OH</td></tr><tr><td colspan="1" rowspan="1">Butyrylcarnitine</td><td colspan="1" rowspan="1">C4</td></tr><tr><td colspan="1" rowspan="1">Methylmalonyl / 3-Hydroxy-isovalerylcarnitine*</td><td colspan="1" rowspan="1">C4DC/C5OH</td></tr><tr><td colspan="1" rowspan="1">Isovalerylcarnitine</td><td colspan="1" rowspan="1">C5</td></tr><tr><td colspan="1" rowspan="1">Tiglylcarnitine</td><td colspan="1" rowspan="1">C5:1</td></tr><tr><td colspan="1" rowspan="1">Glutarylcarnitine / 3-Hydroxy-hexanoylcarnitine*</td><td colspan="1" rowspan="1">C5DC/C6OH</td></tr><tr><td colspan="1" rowspan="1">Hexanoylcarnitine</td><td colspan="1" rowspan="1">C6</td></tr><tr><td colspan="1" rowspan="1">Adipylcarnitine</td><td colspan="1" rowspan="1">C6DC</td></tr><tr><td colspan="1" rowspan="1">Octanoylcarnitine</td><td colspan="1" rowspan="1">C8</td></tr><tr><td colspan="1" rowspan="1">Octenoylcarnitine</td><td colspan="1" rowspan="1">C8:1</td></tr><tr><td colspan="1" rowspan="1">Decanoylcarnitine</td><td colspan="1" rowspan="1">C10</td></tr><tr><td colspan="1" rowspan="1">Decenoylcarnitine</td><td colspan="1" rowspan="1">C10:1</td></tr><tr><td colspan="1" rowspan="1">Decadienoylcarnitine</td><td colspan="1" rowspan="1">C10:2</td></tr><tr><td colspan="1" rowspan="1">Dodecanoylcarnitine</td><td colspan="1" rowspan="1">C12</td></tr><tr><td colspan="1" rowspan="1">ANALYTE NAME</td><td colspan="1" rowspan="1">ABBREVIATION</td></tr><tr><td colspan="2" rowspan="1">Carnitines</td></tr><tr><td colspan="1" rowspan="1">Dodecenoylcarnitine</td><td colspan="1" rowspan="1">C12:1</td></tr><tr><td colspan="1" rowspan="1">Tetradecanoylcarnitine (Myristoylcarnitine)</td><td colspan="1" rowspan="1">C14</td></tr><tr><td colspan="1" rowspan="1">Tetradecenoylcarnitine</td><td colspan="1" rowspan="1">C14:1</td></tr><tr><td colspan="1" rowspan="1">Tetradecadienoylcarnitine</td><td colspan="1" rowspan="1">C14:2</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-tetradecanoylcarnitine</td><td colspan="1" rowspan="1">C140H</td></tr><tr><td colspan="1" rowspan="1">Hexadecanoylcarnitine (palmitoylcarnitine)</td><td colspan="1" rowspan="1">C16</td></tr><tr><td colspan="1" rowspan="1">Hexadecenoylcarnitine</td><td colspan="1" rowspan="1">C16:1</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-hexadecanoylcarnitine</td><td colspan="1" rowspan="1">C160H</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-hexadecenoylcarnitine</td><td colspan="1" rowspan="1">C16:10H</td></tr><tr><td colspan="1" rowspan="1">Octadecanoylcarnitine (Stearoylcarnitine)</td><td colspan="1" rowspan="1">C18</td></tr><tr><td colspan="1" rowspan="1">Octadecenoylcarnitine (Oleylcarnitine)</td><td colspan="1" rowspan="1">C18:1</td></tr><tr><td colspan="1" rowspan="1">Octadecadienoylcarnitine (Linoleylcarnitine)</td><td colspan="1" rowspan="1">C18:2</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-octadecanoylcarnitine</td><td colspan="1" rowspan="1">C18OH</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-octadecenoylcarnitine</td><td colspan="1" rowspan="1">C18:10H</td></tr><tr><td colspan="2" rowspan="1">Ketones</td></tr><tr><td colspan="1" rowspan="1">Succinylacetone</td><td colspan="1" rowspan="1">SA</td></tr></table>

\*Analytes in these rows are either isomers or isobars and cannot be distinguished in the tandem mass spectrometry experiment.

# Device Comparison:

Table 5.1: Comparison of the modified device (NeoBase Non-derivatized MSMS Assay on the TQD Platform_ and predicate device.   

<table><tr><td colspan="3" rowspan="1">GENERAL CHARACTERISTICS</td></tr><tr><td colspan="1" rowspan="1">Parameter</td><td colspan="1" rowspan="1">Modified Device</td><td colspan="1" rowspan="1">Predicate Device</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The NeoBase Non-derivatized MSMSreagent kit is intended for the measurementand evaluation of amino acids,succinylacetone, free carnitine, andacylcarnitine concentrations from newbornheel prick blood samples dried on filterpaper. Quantitative analysis of theseanalytes (Table 1) and their relationshipwith each other is intended to provideanalyte concentration profiles that may aidin screening newborns for metabolicdisorders.(intended use employs a table to identifyeach analyte detected)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">PerkinElmer MS2 Tandem MassSpectrometer System (MS2)PerkinElmer MSMS Quattro Micro (Qmicro)</td><td colspan="1" rowspan="1">- PerkinElmer MS2 TandemMass Spectrometer System- PerkinElmer MS/Ms Qmicro</td></tr><tr><td></td><td>Newborn Screening System PerkinEImer MSMS TQD Newborn Screening System</td><td>Screening System</td></tr></table>

<table><tr><td rowspan=1 colspan=3>GENERAL CHARACTERISTICS</td></tr><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Modified Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Disorders Screened</td><td rowspan=1 colspan=1>Amino-, organic-, and fatty acid metabolicdisorders</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Analytes Measured</td><td rowspan=1 colspan=1>Amino acids, free carnitine, acylcarnitines,and succinylacetone</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Microplate based tandem massspectrometric assay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Test Principle</td><td rowspan=1 colspan=1>Amino acids and carnitines in sample aremeasured by tandem mass spectrometrythrough analyte-specific mass transitionsappropriate for each type of analyte. Theextracted analytes are measured for settime periods and compared to the signalintensities produced by the correspondingisotope-labeled internal standards. Theconcentrations are determined bycomparing the signal intensities of theknown standards to the measured analytes.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Quantitative Nature</td><td rowspan=1 colspan=1>Quantitative by internal standardization</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Requirements</td><td rowspan=1 colspan=1>Newborn blood collected on Schleicher andSchuell 903 filter paper per NCCLSstandards</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Throughput</td><td rowspan=1 colspan=1>Ninety-six tests per microtiter plate. Multipleplates can be analyzed</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Analysis Time</td><td rowspan=1 colspan=1>2 to 2.5 hours per plate.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Controls are blood spots from processedhuman blood enriched with several aminoacids, carnitines and succinylacetone.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Internal calibration using several isotopicallylabeled standards, included as driedmaterial in vials. Internal standards must bereconstituted with extraction solution prior totheir use.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Non-derivatized (analytes measured in theirnative forms)</td><td rowspan=1 colspan=1>Same</td></tr></table>

# Analytes measured by the device

Table 5.2: Analytes measured by the NeoBase kit and their most common abbreviated names   

<table><tr><td colspan="1" rowspan="1">ANALYTE NAME</td><td colspan="1" rowspan="1">ABBREVIATION</td></tr><tr><td colspan="2" rowspan="1">Amino acids</td></tr><tr><td colspan="1" rowspan="1">Alanine</td><td colspan="1" rowspan="1">Ala</td></tr><tr><td colspan="1" rowspan="1">Arginine</td><td colspan="1" rowspan="1">Arg</td></tr><tr><td colspan="1" rowspan="1">Citrulline</td><td colspan="1" rowspan="1">Cit</td></tr><tr><td colspan="1" rowspan="1">Glycine</td><td colspan="1" rowspan="1">Gly</td></tr><tr><td colspan="1" rowspan="1">Leucine/Isoleucine/Hydroxyproline*</td><td colspan="1" rowspan="1">Leu/lle/Pro-OH</td></tr><tr><td colspan="1" rowspan="1">Methionine</td><td colspan="1" rowspan="1">Met</td></tr><tr><td colspan="1" rowspan="1">Onithine</td><td colspan="1" rowspan="1">Orn</td></tr><tr><td colspan="1" rowspan="1">Phenylalanine</td><td colspan="1" rowspan="1">Phe</td></tr><tr><td colspan="1" rowspan="1">Proline</td><td colspan="1" rowspan="1">Pro</td></tr><tr><td colspan="1" rowspan="1">Tyrosine</td><td colspan="1" rowspan="1">Tyr</td></tr><tr><td colspan="1" rowspan="1">Valine</td><td colspan="1" rowspan="1">Val</td></tr><tr><td colspan="1" rowspan="1">Carnitines</td><td colspan="1" rowspan="1">,</td></tr><tr><td colspan="1" rowspan="1">Free carnitine</td><td colspan="1" rowspan="1">CO</td></tr><tr><td colspan="1" rowspan="1">Acetylcarnitine</td><td colspan="1" rowspan="1">C2</td></tr><tr><td colspan="1" rowspan="1">Propionylcarnitine</td><td colspan="1" rowspan="1">C3</td></tr><tr><td colspan="1" rowspan="1">Malonylcarnitine / 3-Hydroxy-butyrylcarnitine*</td><td colspan="1" rowspan="1">C3DC/C4OH</td></tr><tr><td colspan="1" rowspan="1">Butyrylcarnitine</td><td colspan="1" rowspan="1">C4</td></tr><tr><td colspan="1" rowspan="1">MethyImalonyl /3-Hydroxy-isovalerylcarnitine*</td><td colspan="1" rowspan="1">C4DC/C5OH</td></tr><tr><td colspan="1" rowspan="1">Isovalerylcarnitine</td><td colspan="1" rowspan="1">C5</td></tr><tr><td colspan="1" rowspan="1">Tiglylcarnitine</td><td colspan="1" rowspan="1">C5:1</td></tr><tr><td colspan="1" rowspan="1">Glutarylcarnitine / 3-Hydroxy-hexanoylcarnitine*</td><td colspan="1" rowspan="1">C5DC/C6OH</td></tr><tr><td colspan="1" rowspan="1">Hexanoylcarnitine</td><td colspan="1" rowspan="1">C6</td></tr><tr><td colspan="1" rowspan="1">Adipylcarnitine</td><td colspan="1" rowspan="1">C6DC</td></tr><tr><td colspan="1" rowspan="1">Octanoylcarnitine</td><td colspan="1" rowspan="1">C8</td></tr><tr><td colspan="1" rowspan="1">Octenoylcarnitine</td><td colspan="1" rowspan="1">C8:1</td></tr><tr><td colspan="1" rowspan="1">Decanoylcarnitine</td><td colspan="1" rowspan="1">C10</td></tr><tr><td colspan="1" rowspan="1">Decenoylcarnitine</td><td colspan="1" rowspan="1">C10:1</td></tr><tr><td colspan="1" rowspan="1">Decadienoylcarnitine</td><td colspan="1" rowspan="1">C10:2</td></tr><tr><td colspan="1" rowspan="1">Dodecanoylcarnitine</td><td colspan="1" rowspan="1">C12</td></tr><tr><td colspan="1" rowspan="1">Dodecenoylcarnitine</td><td colspan="1" rowspan="1">C12:1</td></tr><tr><td colspan="1" rowspan="1">Tetradecanoylcarnitine (Myristoylcarnitine)</td><td colspan="1" rowspan="1">C14</td></tr><tr><td colspan="1" rowspan="1">Tetradecenoylcarnitine</td><td colspan="1" rowspan="1">C14:1</td></tr><tr><td colspan="1" rowspan="1">Tetradecadienoylcarnitine</td><td colspan="1" rowspan="1">C14:2</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-tetradecanoylcarnitine</td><td colspan="1" rowspan="1">C140H</td></tr><tr><td colspan="1" rowspan="1">Hexadecanoylcarnitine (palmitoylcarnitine)</td><td colspan="1" rowspan="1">C16</td></tr><tr><td colspan="1" rowspan="1">Hexadecenoylcarnitine</td><td colspan="1" rowspan="1">C16:1</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-hexadecanoylcarnitine</td><td colspan="1" rowspan="1">C160H</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-hexadecenoylcarnitine</td><td colspan="1" rowspan="1">C16:10H</td></tr><tr><td colspan="1" rowspan="1">Octadecanoylcarnitine (Stearoylcarnitine)</td><td colspan="1" rowspan="1">C18</td></tr><tr><td colspan="1" rowspan="1">Octadecenoyicarnitine (Oleylcarnitine)</td><td colspan="1" rowspan="1">C18:1</td></tr><tr><td colspan="1" rowspan="1">Octadecadienoylcarnitine (Linoleylcarnitine)</td><td colspan="1" rowspan="1">C18:2</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-octadecanoylcarnitine</td><td colspan="1" rowspan="1">C18OH</td></tr><tr><td colspan="1" rowspan="1">3-Hydroxy-octadecenoylcarnitine</td><td colspan="1" rowspan="1">C18:10H</td></tr><tr><td colspan="1" rowspan="1">Ketones</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Succinylacetone</td><td colspan="1" rowspan="1">SA or SUAC</td></tr></table>

\*Analytes in these rows are either isomers or isobars and cannot be distinguished in the tandem mass spectrometry experiment.

# Substantial equivalency:

# (1) Non-clinical

The performance of the NeoBase Non-derivatized MSMS kit on the PerkinElmer TQD Triple Quadrupole Mass Spectrometer System (PerkinElmer TQD platform) was compared to the predicate $M S ^ { 2 }$ and PerkinElmer Quattro Micro platforms performance, K031878. All of these are tandem mass spectrometry platforms capable of measuring the NeoBase panel of amino acids and acylcarnitines from neonatal dried blood spots. The panel of analytes measured by all three platforms is the same. Analytically, all devices are identical regarding sample requirements, sample processing, analysis time and assay format (Tables 5.1 and 5.2).

The performance of the NeoBase kit on the PerkinElmer TQD platform was compared against the corresponding characteristics reported in the predicate device product insert. A summary of the performance characteristics is presented in Tables 5.3 to 5.6. The NeoBase kit provides equivalent precision, recoveries and measurable ranges that cover all clinically significant ranges on all platforms tested. Therefore, the NeoBase kit provides performance levels that are adequate for its intended use on the ${ \mathsf { M } } { \mathsf { S } } ^ { 2 }$ , PerkinElmer Quattro Micro and PerkinElmer TQD platforms

# Precision

Table 5.3: Averaged Total imprecision for amino acids. Data shown are average Total imprecision coefficients of variation $( \% C \lambda )$ for each platform.   

<table><tr><td rowspan=1 colspan=1>Assay</td><td rowspan=1 colspan=1>ALA</td><td rowspan=1 colspan=1>ARG</td><td rowspan=1 colspan=1>CIT</td><td rowspan=1 colspan=1>GLY</td><td rowspan=1 colspan=1>LEU</td><td rowspan=1 colspan=1>MET</td><td rowspan=1 colspan=1>ORN</td><td rowspan=1 colspan=1>PHE</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>TYR</td><td rowspan=1 colspan=1>VAL</td></tr><tr><td rowspan=1 colspan=1>QM</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>MS²</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>TQD</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>12</td></tr></table>

Table 5.4: Averaged Total imprecision for carnitine and acylcarnitines. Data shown are average Tota imprecision coefficients of variation $( \% C \%$ for each platform.   

<table><tr><td rowspan=1 colspan=1>Assay</td><td rowspan=1 colspan=1>CO</td><td rowspan=1 colspan=1>C2</td><td rowspan=1 colspan=1>C3</td><td rowspan=1 colspan=1>C4</td><td rowspan=1 colspan=1>C5</td><td rowspan=1 colspan=1>C5DC</td><td rowspan=1 colspan=1>C6</td><td rowspan=1 colspan=1>C8</td><td rowspan=1 colspan=1>C10</td><td rowspan=1 colspan=1>C12</td><td rowspan=1 colspan=1>C14</td><td rowspan=1 colspan=1>C16</td><td rowspan=1 colspan=1>C18</td></tr><tr><td rowspan=1 colspan=1>QM</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>MS2</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>TQD</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11</td></tr></table>

# Recovery

Table 5.5: Averaged analyte percent recovery and recovery ranges for all platforms   

<table><tr><td colspan="1" rowspan="2">Analyte</td><td colspan="3" rowspan="1">4Mean % Recovery</td><td colspan="3" rowspan="1">Recovery SD, %</td><td colspan="3" rowspan="1">95% Confidence interval</td></tr><tr><td colspan="1" rowspan="1">TQD</td><td colspan="1" rowspan="1">QMicro</td><td colspan="1" rowspan="1">MS2</td><td colspan="1" rowspan="1">TQD</td><td colspan="1" rowspan="1">QMicro</td><td colspan="1" rowspan="1">MS{2</td><td colspan="1" rowspan="1">TQD</td><td colspan="1" rowspan="1">QMicro</td><td colspan="1" rowspan="1">MS2</td></tr><tr><td colspan="1" rowspan="1">ALA</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">92</td><td colspan="1" rowspan="1">83</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">85-115</td><td colspan="1" rowspan="1">69-116</td><td colspan="1" rowspan="1">63-104</td></tr><tr><td colspan="1" rowspan="1">ARG</td><td colspan="1" rowspan="1">86</td><td colspan="1" rowspan="1">87</td><td colspan="1" rowspan="1">87</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">72-100</td><td colspan="1" rowspan="1">72-102</td><td colspan="1" rowspan="1">73-100</td></tr><tr><td colspan="1" rowspan="1">CIT</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">96</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">82-104</td><td colspan="1" rowspan="1">83-109</td><td colspan="1" rowspan="1">73-116</td></tr><tr><td colspan="1" rowspan="1">GLY</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">86</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">51-128</td><td colspan="1" rowspan="1">69-117</td><td colspan="1" rowspan="1">51-120</td></tr><tr><td colspan="1" rowspan="1">LEU</td><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">88</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">73-128</td><td colspan="1" rowspan="1">72-113</td><td colspan="1" rowspan="1">72-103</td></tr><tr><td colspan="1" rowspan="1">MET</td><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1">88</td><td colspan="1" rowspan="1">86</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">85-110</td><td colspan="1" rowspan="1">75-101</td><td colspan="1" rowspan="1">73-98</td></tr><tr><td colspan="1" rowspan="1">ORN</td><td colspan="1" rowspan="1">98</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">78-117</td><td colspan="1" rowspan="1">75-108</td><td colspan="1" rowspan="1">78-103</td></tr><tr><td colspan="1" rowspan="1">PHE “</td><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">78-109</td><td colspan="1" rowspan="1">81-109</td><td colspan="1" rowspan="1">76-101</td></tr><tr><td colspan="1" rowspan="1">PRO</td><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">84-110</td><td colspan="1" rowspan="1">78-108</td><td colspan="1" rowspan="1">68-100</td></tr><tr><td colspan="1" rowspan="1">SA</td><td colspan="1" rowspan="1">57</td><td colspan="1" rowspan="1">64</td><td colspan="1" rowspan="1">62</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">44-70</td><td colspan="1" rowspan="1">52-77</td><td colspan="1" rowspan="1">48-76</td></tr><tr><td colspan="1" rowspan="1">TYR</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">96</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">72-95</td><td colspan="1" rowspan="1">79-114</td><td colspan="1" rowspan="1">81-122</td></tr><tr><td colspan="1" rowspan="1">VAL</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">88</td><td colspan="1" rowspan="1">78</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">72-109</td><td colspan="1" rowspan="1">69-106</td><td colspan="1" rowspan="1">58-97</td></tr><tr><td colspan="1" rowspan="1">CO</td><td colspan="1" rowspan="1">104</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">107</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">95-114</td><td colspan="1" rowspan="1">70-112</td><td colspan="1" rowspan="1">80-134</td></tr><tr><td colspan="1" rowspan="1">C2  </td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">82-108</td><td colspan="1" rowspan="1">79-108</td><td colspan="1" rowspan="1">80-113</td></tr><tr><td colspan="1" rowspan="1">C3</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">85-102</td><td colspan="1" rowspan="1">78-110</td><td colspan="1" rowspan="1">76-115</td></tr><tr><td colspan="1" rowspan="1">C4.</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">92</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">85-101</td><td colspan="1" rowspan="1">72-109</td><td colspan="1" rowspan="1">64-121</td></tr><tr><td colspan="1" rowspan="1">C5</td><td colspan="1" rowspan="1">86</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">75-97</td><td colspan="1" rowspan="1">78-105</td><td colspan="1" rowspan="1">74-114</td></tr><tr><td colspan="1" rowspan="1">C5DC</td><td colspan="1" rowspan="1">99</td><td colspan="1" rowspan="1">99</td><td colspan="1" rowspan="1">104</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">90-107</td><td colspan="1" rowspan="1">83-115</td><td colspan="1" rowspan="1">87-121</td></tr><tr><td colspan="1" rowspan="1">C6</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">83</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">80-103</td><td colspan="1" rowspan="1">82-101</td><td colspan="1" rowspan="1">63-103</td></tr><tr><td colspan="1" rowspan="1">C8</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">96</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">84-117</td><td colspan="1" rowspan="1">68-113</td><td colspan="1" rowspan="1">70-121</td></tr><tr><td colspan="1" rowspan="1">C10</td><td colspan="1" rowspan="1">92</td><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">85-99</td><td colspan="1" rowspan="1">86-108</td><td colspan="1" rowspan="1">78-112</td></tr><tr><td colspan="1" rowspan="1">C12</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">103</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">93-111</td><td colspan="1" rowspan="1">75-112</td><td colspan="1" rowspan="1">75-130</td></tr><tr><td colspan="1" rowspan="1">C14</td><td colspan="1" rowspan="1">92</td><td colspan="1" rowspan="1">92</td><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">81-104</td><td colspan="1" rowspan="1">82-102</td><td colspan="1" rowspan="1">81-107</td></tr><tr><td colspan="1" rowspan="1">C16</td><td colspan="1" rowspan="1">92</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">83-101</td><td colspan="1" rowspan="1">68-118</td><td colspan="1" rowspan="1">55-114</td></tr><tr><td colspan="1" rowspan="1">C18</td><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">70-109</td><td colspan="1" rowspan="1">77-105</td><td colspan="1" rowspan="1">69-119</td></tr></table>

# Measurable Ranges

Table 5.6: Measurable ranges for both assays and corresponding clinically significant ranges (all in μM/L).   

<table><tr><td colspan="1" rowspan="2">Analyte</td><td colspan="2" rowspan="1">TQD Range (μM)</td><td colspan="2" rowspan="1">QMicro Range^(μM)   </td><td colspan="2" rowspan="1">MS²2 Range (μM)a</td><td colspan="1" rowspan="2">Cutoff Range(μM)</td></tr><tr><td colspan="1" rowspan="1">Lower</td><td colspan="1" rowspan="1">Upper</td><td colspan="1" rowspan="1">Lower</td><td colspan="1" rowspan="1">Upper</td><td colspan="1" rowspan="1">Lower</td><td colspan="1" rowspan="1">Upper</td></tr><tr><td colspan="1" rowspan="1">Ala</td><td colspan="1" rowspan="1">452</td><td colspan="1" rowspan="1">4841</td><td colspan="1" rowspan="1">387</td><td colspan="1" rowspan="1">4090</td><td colspan="1" rowspan="1">444</td><td colspan="1" rowspan="1">4203</td><td colspan="1" rowspan="1">975-1625</td></tr><tr><td colspan="1" rowspan="1">Arg</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">4140</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">3721</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">3806</td><td colspan="1" rowspan="1">180-300</td></tr><tr><td colspan="1" rowspan="1">Cit..</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">1716</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">1683</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">1655</td><td colspan="1" rowspan="1">113-188</td></tr><tr><td colspan="1" rowspan="1">Gly</td><td colspan="1" rowspan="1">309</td><td colspan="1" rowspan="1">4350</td><td colspan="1" rowspan="1">334</td><td colspan="1" rowspan="1">4487</td><td colspan="1" rowspan="1">365</td><td colspan="1" rowspan="1">4504</td><td colspan="1" rowspan="1">975-1625</td></tr><tr><td colspan="1" rowspan="1">Leu</td><td colspan="1" rowspan="1">266</td><td colspan="1" rowspan="1">2992</td><td colspan="1" rowspan="1">218</td><td colspan="1" rowspan="1">2545</td><td colspan="1" rowspan="1">219</td><td colspan="1" rowspan="1">2463</td><td colspan="1" rowspan="1">263438</td></tr><tr><td colspan="1" rowspan="1">Met</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">1252</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">1185</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">1100</td><td colspan="1" rowspan="1">120-200</td></tr><tr><td colspan="1" rowspan="1">Orn</td><td colspan="1" rowspan="1">110</td><td colspan="1" rowspan="1">3914</td><td colspan="1" rowspan="1">115</td><td colspan="1" rowspan="1">3771</td><td colspan="1" rowspan="1">110</td><td colspan="1" rowspan="1">3645</td><td colspan="1" rowspan="1">360600</td></tr><tr><td colspan="1" rowspan="1">Phe</td><td colspan="1" rowspan="1">79</td><td colspan="1" rowspan="1">2607</td><td colspan="1" rowspan="1">71</td><td colspan="1" rowspan="1">2341</td><td colspan="1" rowspan="1">73</td><td colspan="1" rowspan="1">2169</td><td colspan="1" rowspan="1">225375</td></tr><tr><td colspan="1" rowspan="1">Pro</td><td colspan="1" rowspan="1">248</td><td colspan="1" rowspan="1">3735</td><td colspan="1" rowspan="1">251</td><td colspan="1" rowspan="1">3659</td><td colspan="1" rowspan="1">238</td><td colspan="1" rowspan="1">3327</td><td colspan="1" rowspan="1">450-750</td></tr><tr><td colspan="1" rowspan="1">SA</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">164.9</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">158.1</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">155.0</td><td colspan="1" rowspan="1">4-7.0</td></tr><tr><td colspan="1" rowspan="1">Tyr</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">2980</td><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">2816</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">2857</td><td colspan="1" rowspan="1">578-963</td></tr><tr><td colspan="1" rowspan="1">Val</td><td colspan="1" rowspan="1">197</td><td colspan="1" rowspan="1">2300</td><td colspan="1" rowspan="1">205</td><td colspan="1" rowspan="1">2358</td><td colspan="1" rowspan="1">176</td><td colspan="1" rowspan="1">1902</td><td colspan="1" rowspan="1">300-500</td></tr><tr><td colspan="1" rowspan="1">CO</td><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">2930</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">2274</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">2386</td><td colspan="1" rowspan="1">90-150</td></tr><tr><td colspan="1" rowspan="1">C2</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">743</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">735</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">745</td><td colspan="1" rowspan="1">128213</td></tr><tr><td colspan="1" rowspan="1">C3</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">96</td><td colspan="1" rowspan="1">3.1</td><td colspan="1" rowspan="1">88</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">9.7516.25</td></tr><tr><td colspan="1" rowspan="1">C4</td><td colspan="1" rowspan="1">0.20</td><td colspan="1" rowspan="1">70.8</td><td colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1">59.8</td><td colspan="1" rowspan="1">0.13</td><td colspan="1" rowspan="1">57</td><td colspan="1" rowspan="1">2.253.75</td></tr><tr><td colspan="1" rowspan="1">C5 </td><td colspan="1" rowspan="1">0.20</td><td colspan="1" rowspan="1">62.9</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">59.1</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1">59.9</td><td colspan="1" rowspan="1">1.883.13</td></tr><tr><td colspan="1" rowspan="1">C5DC!</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">32.6</td><td colspan="1" rowspan="1">0.13</td><td colspan="1" rowspan="1">28.9</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">29.2</td><td colspan="1" rowspan="1">0.6-1</td></tr><tr><td colspan="1" rowspan="1">C6</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">67.6</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">61.5</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">66.6</td><td colspan="1" rowspan="1">0.98-1.63</td></tr><tr><td colspan="1" rowspan="1">C8 :</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">39.8</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">35.2</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">35.8</td><td colspan="1" rowspan="1">1.2-2</td></tr><tr><td colspan="1" rowspan="1">C10</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">29.8</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">28.9</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">27.9</td><td colspan="1" rowspan="1">1.352.25</td></tr><tr><td colspan="1" rowspan="1">C12</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">50.8</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">42.7</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">41.7</td><td colspan="1" rowspan="1">1.883.13</td></tr><tr><td colspan="1" rowspan="1">C14.</td><td colspan="1" rowspan="1">0.1</td><td colspan="1" rowspan="1">42.7</td><td colspan="1" rowspan="1">0.1</td><td colspan="1" rowspan="1">41.8</td><td colspan="1" rowspan="1">0.1</td><td colspan="1" rowspan="1">42.3</td><td colspan="1" rowspan="1">1.5-2.5</td></tr><tr><td colspan="1" rowspan="1">C16</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">90.5</td><td colspan="1" rowspan="1">2.8</td><td colspan="1" rowspan="1">107.3</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">106.7</td><td colspan="1" rowspan="1">11.25-18.75</td></tr><tr><td colspan="1" rowspan="1">C18</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">34    I</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">35.0</td></tr></table>

# Method Correlation

An additional measure of the equivalency in the results obtained when the assay is executed using three platforms is the comparison of the actual measured concentrations for each of the analytes included in dried blood spots enriched with the analytes of interest. The raw data was matched per run per level for two comparisons: 1) $M S ^ { 2 }$ to PerkinElmer TQD; and 2) PerkinElmer Q Micro to TQD. Means were calculated per run per analyte per spiked level, to result in 25 means per platform for each analyte (5 levels times 5 runs per analyte). The results were averaged over the five spiked levels and the ratios of the means (per analyte) were then determined for the two comparisons $( { \mathsf { M } } { \mathsf { S } } ^ { 2 } / { \mathsf { T } } { \mathsf { Q } } { \mathsf { D } }$ and Q Micro/TQD). If the two platforms being compared give equivalent concentration measurements, then the ratio will be 1.0. The mean ratio (averaged over five levels) of each analyte is presented in Tables 5.7 and 5.8 for the $M S ^ { 2 } / \top \mathsf { Q D }$ and Q Micro/TQD comparisons, respectively.

Table 5.7: Mean ratio of measured concentration for $M S ^ { 2 } / T Q D$ comparison. Mean ratios of 25 measurements shown along with corresponding SD, $\% c v$ , and upper and lower $9 5 \%$ confidence limits.   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>ALA</td><td rowspan=1 colspan=1>ARG</td><td rowspan=1 colspan=1>CIT</td><td rowspan=1 colspan=1>GLY</td><td rowspan=1 colspan=1>LEU</td><td rowspan=1 colspan=1>MET</td><td rowspan=1 colspan=1>ORN</td><td rowspan=1 colspan=1>PHE</td><td rowspan=12 colspan=1></td></tr><tr><td rowspan=17 colspan=1>WOSW</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>1.09</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.89</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.03</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>LCL</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>0.86</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>0.94</td><td rowspan=1 colspan=1>0.83</td></tr><tr><td rowspan=1 colspan=1>UCL</td><td rowspan=1 colspan=1>1.22</td><td rowspan=1 colspan=1>1.05</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>1.17</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>1.05</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>0.95</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>PRO</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>.TYR</td><td rowspan=1 colspan=1>VAL</td><td rowspan=1 colspan=1>CO</td><td rowspan=1 colspan=1>C2</td><td rowspan=1 colspan=1>C3</td><td rowspan=1 colspan=1>C4</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>0.94</td><td rowspan=1 colspan=1>1.08</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>1.08</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>0.92</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.03</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>LCL</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.86</td></tr><tr><td rowspan=1 colspan=1>UCL</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.17</td><td rowspan=1 colspan=1>1.06</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>1.05</td><td rowspan=1 colspan=1>1.05</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>0.98</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>C5</td><td rowspan=1 colspan=1>C5DC</td><td rowspan=1 colspan=1>C6</td><td rowspan=1 colspan=1>C8</td><td rowspan=1 colspan=1>C10</td><td rowspan=1 colspan=1>C12</td><td rowspan=1 colspan=1>C14</td><td rowspan=1 colspan=1>C16</td><td rowspan=1 colspan=1>C18</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.94</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.04</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>LCL</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.82</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>0.94</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>0.92</td></tr><tr><td rowspan=1 colspan=1>UCL</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>1.06</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.06</td><td rowspan=1 colspan=1>1.09</td><td rowspan=1 colspan=1>1.06</td><td rowspan=1 colspan=1>1.06</td></tr></table>

Table 5.8: Mean ratio of measured concentration for Q Micro/TQD comparison. Mean ratios of 25 measurements shown along with corresponding SD, %CV, and upper and lower 95% confidence limits.   

<table><tr><td colspan="2" rowspan="1">$</td><td colspan="1" rowspan="1">ALA</td><td colspan="1" rowspan="1">ARG</td><td colspan="1" rowspan="1">CIT</td><td colspan="1" rowspan="1">GLY</td><td colspan="1" rowspan="1">LEU</td><td colspan="1" rowspan="1">MET</td><td colspan="1" rowspan="1">ORN</td><td colspan="1" rowspan="1">PHE</td></tr><tr><td colspan="1" rowspan="2">pMo</td><td colspan="1" rowspan="1">Mean</td><td colspan="1" rowspan="1">0.92</td><td colspan="1" rowspan="1">1.00</td><td colspan="1" rowspan="1">1.00</td><td colspan="1" rowspan="1">0.98</td><td colspan="1" rowspan="1">1.01</td><td colspan="1" rowspan="1">1.08</td><td colspan="1" rowspan="1">1.06</td><td colspan="1" rowspan="1">0.97</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.06</td></tr><tr><td colspan="1" rowspan="1">% CV</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">6 ·</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="9"></td></tr><tr><td colspan="1" rowspan="1">LCL</td><td colspan="1" rowspan="1">0.84</td><td colspan="1" rowspan="1">0.90</td><td colspan="1" rowspan="1">0.87</td><td colspan="1" rowspan="1">0.88</td><td colspan="1" rowspan="1">0.90</td><td colspan="1" rowspan="1">1.00</td><td colspan="1" rowspan="1">0.98</td><td colspan="1" rowspan="1">0.84</td></tr><tr><td colspan="1" rowspan="1">UCL</td><td colspan="1" rowspan="1">0.99</td><td colspan="1" rowspan="1">1.11</td><td colspan="1" rowspan="1">1.13</td><td colspan="1" rowspan="1">1.07</td><td colspan="1" rowspan="1">1.12.</td><td colspan="1" rowspan="1">1.16</td><td colspan="1" rowspan="1">1.14</td><td colspan="1" rowspan="1">1.09</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">PRO</td><td colspan="1" rowspan="1">SA</td><td colspan="1" rowspan="1">TYR </td><td colspan="1" rowspan="1">VAL</td><td colspan="1" rowspan="1">CO</td><td colspan="1" rowspan="1">C2</td><td colspan="1" rowspan="1">C3.</td><td colspan="1" rowspan="1">C4</td></tr><tr><td colspan="1" rowspan="1">Mean</td><td colspan="1" rowspan="1">1.02</td><td colspan="1" rowspan="1">1.04</td><td colspan="1" rowspan="1">1.00</td><td colspan="1" rowspan="1">1.08</td><td colspan="1" rowspan="1">0.99</td><td colspan="1" rowspan="1">0.94</td><td colspan="1" rowspan="1">0.95</td><td colspan="1" rowspan="1">1.03</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.04</td></tr><tr><td colspan="1" rowspan="1">% CV</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1">LCL</td><td colspan="1" rowspan="1">0.95</td><td colspan="1" rowspan="1">0.96</td><td colspan="1" rowspan="1">0.91</td><td colspan="1" rowspan="1">0.95</td><td colspan="1" rowspan="1">0.93</td><td colspan="1" rowspan="1">0.86</td><td colspan="1" rowspan="1">0.87</td><td colspan="1" rowspan="1">0.96</td></tr><tr><td colspan="1" rowspan="1">UCL</td><td colspan="1" rowspan="1">1.09</td><td colspan="1" rowspan="1">1.13</td><td colspan="1" rowspan="1">1.10</td><td colspan="1" rowspan="1">1.21</td><td colspan="1" rowspan="1">1.05</td><td colspan="1" rowspan="1">1.02</td><td colspan="1" rowspan="1">1.04</td><td colspan="1" rowspan="1">1.10</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">C5</td><td colspan="1" rowspan="1">C5DC</td><td colspan="1" rowspan="1">C6</td><td colspan="1" rowspan="1">C8</td><td colspan="1" rowspan="1">C10</td><td colspan="1" rowspan="1">C12</td><td colspan="1" rowspan="1">C14</td><td colspan="1" rowspan="1">C16</td><td colspan="1" rowspan="1">C18</td></tr><tr><td colspan="1" rowspan="1">Mean</td><td colspan="1" rowspan="1">0.97</td><td colspan="1" rowspan="1">0.97</td><td colspan="1" rowspan="1">1.00</td><td colspan="1" rowspan="1">1.00</td><td colspan="1" rowspan="1">0.98</td><td colspan="1" rowspan="1">1.02</td><td colspan="1" rowspan="1">1.00</td><td colspan="1" rowspan="1">1.00</td><td colspan="1" rowspan="1">1.02</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.04</td></tr><tr><td colspan="1" rowspan="1">% CV</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1">LCL</td><td colspan="1" rowspan="1">0.91</td><td colspan="1" rowspan="1">0.91</td><td colspan="1" rowspan="1">0.93</td><td colspan="1" rowspan="1">0.94</td><td colspan="1" rowspan="1">0.92</td><td colspan="1" rowspan="1">0.96</td><td colspan="1" rowspan="1">0.93</td><td colspan="1" rowspan="1">0.93</td><td colspan="1" rowspan="1">0.95</td></tr><tr><td colspan="1" rowspan="1">UCL</td><td colspan="1" rowspan="1">1.03</td><td colspan="1" rowspan="1">1.03</td><td colspan="1" rowspan="1">1.07</td><td colspan="1" rowspan="1">1.07</td><td colspan="1" rowspan="1">1.05</td><td colspan="1" rowspan="1">1.09</td><td colspan="1" rowspan="1">1.07</td><td colspan="1" rowspan="1">1.08</td><td colspan="1" rowspan="1">1.10</td></tr></table>

The ratios range from 0.89 to 1.09 for the MS2/TQD comparison. Taking into account the small variation, the results indicate these two platforms give statistically equivalent results. Likewise, the ratios range from 0.92 to 1.08 for the Q Micro/TQD comparison and noting the small variation in the mean ratios, the results indicate these two platforms give statistically equivalent results.

# (2) Clinical CLINICAL CORRELATION STUDIES

The clinical correlation studies involved the analysis of 2499 random newborn screening specimens and 17 specimens with true positive diagnoses. In addition, a set of enriched samples (five levels) was analyzed (as singlicates of each level) for 16 runs to provide a total of 80 individual measurements. All samples were evaluated in parallel on the TQD and the predicate ${ \mathsf { M } } { \mathsf { S } } ^ { 2 }$ platforms using the NeoBase kit. Clinical correlation was established by assessing whether or not the platforms were concordant in determining the paired samples to have analyte concentration values above or below their corresponding cutoffs. Examination on the number of concordant pairs for each analyte (cases in which both methods agreed) provided the percent agreements shown in Table 5.9.

Table 5.9: Percent agreement in clinical determinations between the TQD and $M S ^ { 2 }$ platforms.   

<table><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Total # ofobservations</td><td colspan="1" rowspan="1">%agreement</td><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Total # ofobservations</td><td colspan="1" rowspan="1">%agreement</td></tr><tr><td colspan="1" rowspan="1">ALA</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.6%</td><td colspan="1" rowspan="1">C14</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.9%</td></tr><tr><td colspan="1" rowspan="1">ARG</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.9%</td><td colspan="1" rowspan="1">C16</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.6%</td></tr><tr><td colspan="1" rowspan="1">CIT</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.8%</td><td colspan="1" rowspan="1">C18</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.9%</td></tr><tr><td colspan="1" rowspan="1">GLY</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.5%</td><td colspan="1" rowspan="1">C4OH/C3DC</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.9%</td></tr><tr><td colspan="1" rowspan="1">LEU</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.6%</td><td colspan="1" rowspan="1">C5OH/C4DC</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.9%</td></tr><tr><td colspan="1" rowspan="1">MET</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">100.0%</td><td colspan="1" rowspan="1">C5:1</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.4%</td></tr><tr><td colspan="1" rowspan="1">ORN</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.6%</td><td colspan="1" rowspan="1">C6DC</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.8%</td></tr><tr><td colspan="1" rowspan="1">PHE</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.9%</td><td colspan="1" rowspan="1">C8:1</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.9%</td></tr><tr><td colspan="1" rowspan="1">PRO</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.8%</td><td colspan="1" rowspan="1">C10:1</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">100.0%</td></tr><tr><td colspan="1" rowspan="1">SA</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.5%</td><td colspan="1" rowspan="1">C10:2</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.7%</td></tr><tr><td colspan="1" rowspan="1">TYR</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.2%</td><td colspan="1" rowspan="1">C12:1</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">100.0%</td></tr><tr><td colspan="1" rowspan="1">VAL</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.7%</td><td colspan="1" rowspan="1">C14-OH</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.7%</td></tr><tr><td colspan="1" rowspan="1">CO</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">100.0%</td><td colspan="1" rowspan="1">C14:1</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.8%</td></tr><tr><td colspan="1" rowspan="1">C2</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.9%</td><td colspan="1" rowspan="1">C14:2</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.8%</td></tr><tr><td colspan="1" rowspan="1">C3</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">100.0%</td><td colspan="1" rowspan="1">C16-OH</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.8%</td></tr><tr><td colspan="1" rowspan="1">C4</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.9%</td><td colspan="1" rowspan="1">C16:1</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.9%</td></tr><tr><td colspan="1" rowspan="1">C5</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.9%</td><td colspan="1" rowspan="1">C16:1-OH</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.8%</td></tr><tr><td colspan="1" rowspan="1">C5DC</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.7%</td><td colspan="1" rowspan="1">C18-OH</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.6%</td></tr><tr><td colspan="1" rowspan="1">C6</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.7%</td><td colspan="1" rowspan="1">C18:1</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.9%</td></tr><tr><td colspan="1" rowspan="1">C8</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.8%</td><td colspan="1" rowspan="1">C18:1-OH</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">99.2%</td></tr><tr><td colspan="1" rowspan="1">C10</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.9%</td><td colspan="1" rowspan="1">C18:2</td><td colspan="1" rowspan="1">2518*</td><td colspan="1" rowspan="1">100.0%</td></tr><tr><td colspan="1" rowspan="1">C12</td><td colspan="1" rowspan="1">2598</td><td colspan="1" rowspan="1">99.8%</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr></table>

For these analytes, newborn screening samples (presumptive negative data t, $\scriptstyle 1 = 2 4 9 9$ )and true positives $( n = 1 9$ , include the newly acquired NKH and H-ALA samples) were used.

# COMPARISON OF TRUE POSITIVE SAMPLE RESULTS BETWEEN PLATFORM

The correlation between the test and predicate platforms included 17 samples with true positive diagnoses representing 14 disorders (Table 5.10). All of these cases were successfully detected by both platforms for $100 \%$ agreement in the clinical determination (Table 5.10).

Table 5.10; Summary of the analysis of true Positive samples by the NeoBase assay when performec on the MS² and TQD platforms   

<table><tr><td colspan="1" rowspan="2">Sample</td><td colspan="1" rowspan="2">Disorder</td><td colspan="2" rowspan="1">*CasesDetected</td><td colspan="2" rowspan="1">Elevated Analytes Detected by each Platform</td></tr><tr><td colspan="1" rowspan="1">TQD</td><td colspan="1" rowspan="1">Sciex</td><td colspan="1" rowspan="1">TQD</td><td colspan="1" rowspan="1">Sciex</td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">TYRI</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">SA, TYR</td><td colspan="1" rowspan="1">SA, TYR</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">CPT II</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">C12, C14, C16,C16:1, C16:1 OH,C16-OH, C18, C18:1,C18:1-OH</td><td colspan="1" rowspan="1">C14, C14:OH, C16,C16:1, C16:1 OH, C16-OH, C18, C18:1, C18:1-OH, C18-OH</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">MMA</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">C3, C6,</td><td colspan="1" rowspan="1">C3</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">HMG</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">C5OH/C4DC,, C6DC</td><td colspan="1" rowspan="1">C5OH/C4DC</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">VLCAD</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">C14:1</td><td colspan="1" rowspan="1">C14:1</td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">IVA</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">C5.</td><td colspan="1" rowspan="1">C5</td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">MCC</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">C5OH/C4DC</td><td colspan="1" rowspan="1">C5OH/C4DC</td></tr><tr><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">BTK</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">CO, C4, C5:1, C6, C8</td><td colspan="1" rowspan="1">CO, C4, C5:1,</td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">MSUD</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">LEU</td><td colspan="1" rowspan="1">LEU</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">MCAD</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">C6, C8, C10:1</td><td colspan="1" rowspan="1">CO low, C8, C10:1</td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">PPA</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">C3, C16:1 OH</td><td colspan="1" rowspan="1">C3, C16:1 OH</td></tr><tr><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">PKU</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">PHE</td><td colspan="1" rowspan="1">PHE</td></tr><tr><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">CIT</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">CIT</td><td colspan="1" rowspan="1">CIT</td></tr><tr><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">PKU</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">PHE</td><td colspan="1" rowspan="1">PHE</td></tr><tr><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">MCAD</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">C6, C6DC, C8, C10,C10:1, C12:1</td><td colspan="1" rowspan="1">C6, C6DC, C8, C10,C10:1</td></tr><tr><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">GAI</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">C5DC</td><td colspan="1" rowspan="1">C5DC</td></tr><tr><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">PKU</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">yes</td><td colspan="1" rowspan="1">PHE</td><td colspan="1" rowspan="1">PHE</td></tr></table>

Finally, the established performance characteristics and method comparison at the analytical and clinical levels show that using the Neo Base Non-derivatized MSMS kit on the PerkinElmer TQD platform provides performance that is equivalent to the performance of the kit when used on the predicate platforms.

PerkinElmer   
c/o Kay Taylor   
Director, Regulatory and Clinical Affairs   
8275 Carloway Road   
Indiannapolis, IN 46236

AUG 2 3 2010

Re: k093916 Trade Name: NeoBase Non-derivatized MSMS reagent kit Regulation Number: 21 CFR 862.1055 Regulation Name: Newborn screening test system for amino acids, free carnitine, and acylcarnitines using tandem mass spectrometry Regulatory Class: Class II Product Codes: NQL Dated: August 10, 2010 Received: August 11, 2010

Dear Ms. Taylor:

We have reviewed your Section $5 1 0 ( \mathbf k )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject tö such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/8616038b2242466583d6b605fcdcf4ef07dda3492cc386016d37ecfc84bf0fc8.jpg)

Courtny C. Harper, Ph.D.   
Directr   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Indications for Use Form

510(k) Number (if known): K093916

# Device Name: NeoBase Non-derivatized MSMS Kit

Indications for Use:

The Neobase Non-derivatized MSMS reagent kit (for use on the PerkinElmer TQD MSMS Screening System) is intended for the measurement and evaluation of amino acids, succinylacetone, free carnitine, and acylcarnitine concentrations from newborn heel prick blood samples dried on filter paper.

Quantitative analysis of these analytes (Table 1) and their relationship with each other is intended to provide analyte concentration profiles that may aid in screening newborns for metabolic disorders.

Table 1. Analytes measured by the NeoBase ™ Non-derivatized MSMS Kit.   

<table><tr><td rowspan=1 colspan=1>ANALYTE NAME</td><td rowspan=1 colspan=1>ABBREVIATION</td></tr><tr><td rowspan=1 colspan=2>Amino acids</td></tr><tr><td rowspan=1 colspan=1>Alanine</td><td rowspan=1 colspan=1>Ala</td></tr><tr><td rowspan=1 colspan=1>Arginine</td><td rowspan=1 colspan=1>Arg</td></tr><tr><td rowspan=1 colspan=1>Citrulline</td><td rowspan=1 colspan=1>Cit</td></tr><tr><td rowspan=1 colspan=1>Glycine</td><td rowspan=1 colspan=1>Gly</td></tr><tr><td rowspan=1 colspan=1>Leucine/Isoleucine/Hydroxyproline*</td><td rowspan=1 colspan=1>Leu/Ile/Pro-OH</td></tr><tr><td rowspan=1 colspan=1>Methionine</td><td rowspan=1 colspan=1>Met</td></tr><tr><td rowspan=1 colspan=1>Ornithine</td><td rowspan=1 colspan=1>Or</td></tr><tr><td rowspan=1 colspan=1>Phenylalanine</td><td rowspan=1 colspan=1>Phe</td></tr><tr><td rowspan=1 colspan=1>Proline</td><td rowspan=1 colspan=1>Pro</td></tr><tr><td rowspan=1 colspan=1>Tyrosine</td><td rowspan=1 colspan=1>Tyr</td></tr><tr><td rowspan=1 colspan=1>Valine</td><td rowspan=1 colspan=1>Val</td></tr></table>

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

CalC.Benam

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

<table><tr><td rowspan=1 colspan=1>ANALYTE NAME (continued)</td><td rowspan=1 colspan=1>ABBREVIATION</td></tr><tr><td rowspan=1 colspan=1>Carnitines</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Free carnitine</td><td rowspan=1 colspan=1>CO</td></tr><tr><td rowspan=1 colspan=1>Acetylcarnitine</td><td rowspan=1 colspan=1>C2</td></tr><tr><td rowspan=1 colspan=1>Propionylcarnitine</td><td rowspan=1 colspan=1>C3</td></tr><tr><td rowspan=1 colspan=1>Malonylcarnitine / 3-Hydroxy-butyrylcarnitine*</td><td rowspan=1 colspan=1>C3DC/C4OH</td></tr><tr><td rowspan=1 colspan=1>Butyrylcarnitine</td><td rowspan=1 colspan=1>C4</td></tr><tr><td rowspan=1 colspan=1>Methylmalonyl/ 3-Hydroxy-isovalerylcarnitine*</td><td rowspan=1 colspan=1>C4DC/C50H</td></tr><tr><td rowspan=1 colspan=1>Isovalerylcarnitine</td><td rowspan=1 colspan=1>C5</td></tr><tr><td rowspan=1 colspan=1>Tiglylcarnitine</td><td rowspan=1 colspan=1>C5:1</td></tr><tr><td rowspan=1 colspan=1>Glutarylcarnitine / 3-Hydroxy-hexanoylcarnitine *</td><td rowspan=1 colspan=1>CSDC/C6OH</td></tr><tr><td rowspan=1 colspan=1>Hexanoylcarnitine</td><td rowspan=1 colspan=1>C6</td></tr><tr><td rowspan=1 colspan=1>Adipylcarnitine</td><td rowspan=1 colspan=1>C6DC</td></tr><tr><td rowspan=1 colspan=1>Octanoylcarnitine</td><td rowspan=1 colspan=1>C8</td></tr><tr><td rowspan=1 colspan=1>Octenoylcarnitine</td><td rowspan=1 colspan=1>C8:1</td></tr><tr><td rowspan=1 colspan=1>Decanoylcarnitine</td><td rowspan=1 colspan=1>C10</td></tr><tr><td rowspan=1 colspan=1>Decenoylcarnitine</td><td rowspan=1 colspan=1>C10:1</td></tr><tr><td rowspan=1 colspan=1>Decadienoylcarnitine</td><td rowspan=1 colspan=1>C10:2</td></tr><tr><td rowspan=1 colspan=1>Dodecanoylcarnitine</td><td rowspan=1 colspan=1>C12</td></tr><tr><td rowspan=1 colspan=1>Dodecenoylcarnitine</td><td rowspan=1 colspan=1>C12:1</td></tr><tr><td rowspan=1 colspan=1>Tetradecanoylcarnitine (Myristoylcarnitine)</td><td rowspan=1 colspan=1>C14</td></tr><tr><td rowspan=1 colspan=1>Tetradecenoylcarnitine</td><td rowspan=1 colspan=1>C14:1</td></tr><tr><td rowspan=1 colspan=1>Tetradecadienoylcarnitine</td><td rowspan=1 colspan=1>C14:2</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-tetradecanoylcarnitine</td><td rowspan=1 colspan=1>C140H</td></tr><tr><td rowspan=1 colspan=1>Hexadecanoylcarnitine (Palmitoylcarnitine)</td><td rowspan=1 colspan=1>C16</td></tr><tr><td rowspan=1 colspan=1>Hexadecenoylcarnitine</td><td rowspan=1 colspan=1>C16:1</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-hexadecanoylcarnitine</td><td rowspan=1 colspan=1>C16OH</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-hexadecenoylcarnitine</td><td rowspan=1 colspan=1>C16:10H</td></tr></table>

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/c342fa574cca73f69d40b63d187e5a8b9d88881c5d9a9e84b3b701e8478f7105.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

<table><tr><td rowspan=1 colspan=1>ANALYTE NAME (continued)</td><td rowspan=1 colspan=1>ABBREVIATION</td></tr><tr><td rowspan=1 colspan=1>Octadecanoylcarnitine (StearoyIcarnitine)</td><td rowspan=1 colspan=1>C18</td></tr><tr><td rowspan=1 colspan=1>Octadecenoylcarnitine (Oleylcarnitine)</td><td rowspan=1 colspan=1>C18:1</td></tr><tr><td rowspan=1 colspan=1>Octadecadienoylcarnitine (Linoleylcarnitine)</td><td rowspan=1 colspan=1>C18:2</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-octadecanoylcarnitine</td><td rowspan=1 colspan=1>C18OH</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxy-octadecenoylcarnitine</td><td rowspan=1 colspan=1>C18:10H</td></tr><tr><td rowspan=1 colspan=2>Ketones</td></tr><tr><td rowspan=1 colspan=1>Succinylacetone</td><td rowspan=1 colspan=1>SA</td></tr></table>

Analyte  the ows eithisomers  sobars an cannot be istinguised n the tandem ma pectrometry experiment.

# (PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/58d4fb58c614ba87bc192fb638f561e175fce4d22adf6a6236e9a29069991e40.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety